

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

1-14. (Canceled)

15. (Previously presented) A method of treatment of a host with a cellular proliferative disease, comprising contacting said host with amonafide in conjunction with homoharringtonine, each in an amount sufficient to have an anticancer effect on said cellular proliferative disease, wherein said cellular proliferative disease is a solid tumor.

16. (Previously presented) A method according to claim 1 wherein said amonafide is administered before the administration of said homoharringtonine.

17. (Previously presented) A method according to claim 1 wherein said amonafide is administered during the administration of said homoharringtonine.

18. (Previously presented) A method according to claim 1 wherein said amonafide is administered after the administration of said homoharringtonine.

19. (Previously presented) The method according to claim 1 wherein said anticancer effect of said amonafide and said homoharringtonine on said cellular proliferative disease is greater than that for said amonafide or said homoharringtonine alone.

20 & 21. (Canceled)

22. (Previously presented) The method according to claim 21 wherein said anticancer effect is a chemopotentiating effect.

23. (Previously presented) The method according to claim 21 wherein said anticancer effect is a cytostatic effect on increase in tumor volume quadrupling time.

24. (Previously presented) The method according to claim 21 wherein said anticancer effect is an increase in tumor volume quadrupling time.

25. (Previously presented) A composition comprising amonafide and homoharringtonine, wherein the modulation of a cellular proliferative disease by amonafide and homoharringtonine is greater than that for amonafide or homoharringtonine alone.

26. (Previously presented) A method of treatment of a host with a cellular proliferative disease, comprising contacting said host with amonafide in conjunction with homoharringtonine, each in an amount sufficient to have an anticancer effect on said cellular proliferative disease, wherein said cellular proliferative disease is a solid tumor, and wherein the treatment with amonafide in conjunction with homoharringtonine is more effective than the treatment with homoharringtonine alone.

27-30. (Canceled)